On August 25, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported corporate highlights and financial results for the first half of 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The first half of 2026 was marked by strong execution across our pipeline. With MP0712, a DLL3-targeting Radio-DARPin, we have treated the first patients in our SCLC trial, and dose escalation in the Phase 1/2a study is progressing as planned. To further strengthen our Radio pipeline, we selected CD70 as our next target, which will be evaluated using an isotope-agnostic approach. Backed by a strong balance sheet that funds operations into late 2027, we remain focused on delivering key value-driving milestones, including initial clinical data from MP0712 later this year and continued advancement of our pipeline," said Patrick Amstutz, Ph.D., CEO of Molecular Partners.

In addition, the Company reported that its lead Radio-DARPin candidate MP0712 has progressed to the next therapeutic dose level (cohort 2) in the Phase 1/2a study.

"Opening of cohort 2 in the Phase 1 study marks an important milestone for the MP0712 program. With any investigational drug, safety is paramount. We are happy to see that our assumptions with regard to blood and general safety remain well intact. We now move to the higher therapeutic dose level with confidence and look forward to the continued good collaboration with the investigators and sites," said Philippe Legenne, M.D., CMO of Molecular Partners.

Research & Development Highlights

MP0712 (DLL3-targeting Radio-DARPin Therapy, RDT)

MP0712, targeting the tumor-associated antigen delta-like ligand 3 (DLL3) and carrying the therapeutic alpha-emitting payload 212Pb, is being co-developed with strategic partner Orano Med, pioneer in the development of 212Pb-based targeted alpha therapies, for the treatment of small cell lung cancer (SCLC) and other neuroendocrine cancers.

The U.S. multicenter Phase 1/2a study of MP0712 (NCT07278479) is well underway with the first dose level (cohort 1) fully recruited. Repeat dosing is ongoing, with patients receiving as many as four doses of MP0712 to date. All patients in cohort 1 (75 MBq per dose) passed the safety observation period, with no dose-limiting events observed. All adverse events reported to date were mild to moderate (grade 1–2) and transient, resolving in time for the next regular dosing cycle. After review of the safety data of cohort 1, the Dose Escalation Review Committee recommended that the Company proceed to dosing patients at the next therapeutic dose level (cohort 2, 105 MBq per dose). Cohort 2 is now open and recruiting patients. Five study sites are active, with a total of nine sites expected to be open in 2026. In total, four dose levels are planned in the Phase 1. The Company expects to report initial clinical data in 2026, followed by a more comprehensive safety and efficacy dataset in 2027.

Next RDT Programs

Molecular Partners pursues an isotope-agnostic strategy for its pipeline of targeted alpha therapeutics. The versatility of DARPins allows interchangeability of alpha isotopes, including 212Pb and 225Ac and corresponding chelators, enabling candidates to be tailored to a specific target and disease biology.

The Company communicated in July 2026 that it intends to advance MSLN-targeting MP0726, its second RDT program, to first-in-human imaging in H2 2026. In addition, the Nuclear Medicine Research Institute (NuMeRI) has initiated an early-access clinical program utilizing a DLL3-targeting Radio-DARPin labeled with 177Lu/225Ac (referred to as MP0714) to image and treat patients in South Africa. Molecular Partners remains fully focused on the execution of the US Phase 1/2a study of MP0712 with 212Pb.

As part of its growing portfolio Molecular Partners has selected CD70, a clinically validated tumor-associated antigen as the third target for its RDT pipeline. CD70 is overexpressed in clear cell renal cell carcinoma (ccRCC, a type of kidney cancer) and other cancer indications, with limited expression in healthy tissues, making it an attractive candidate for targeted radiopharmaceutical therapy. Targeted alpha therapy has the potential to overcome resistance mechanisms reported for chemotherapy and other therapeutic modalities in ccRCC. The Company intends to present supporting pre-clinical data at a scientific congress in H2 2026. IND-enabling work will begin in H2 2026, and the program is slated to enter the clinic in 2027.

Immune Cell Engagers

As highlighted in July 2026, MP0317, a FAP-localized CD40 agonist, is progressing in an investigator-initiated randomized Phase 2 proof-of-concept study in patients with advanced cholangiocarcinoma (NCT07036380). Nine study sites are active in France and patient treatment ongoing. The study aims to assess whether adding MP0317 to standard of care – durvalumab (anti-PDL1) plus gemcitabine-cisplatin chemotherapy – improves the 12-month progression-free survival rate of these patients.

The dose escalation of the Phase 1/2a trial of MP0533, a novel tetra-specific T cell engager designed for selective mutation-agnostic killing of AML cells, is fully recruited, with last patients currently on treatment (NCT05673057). The results of the study support exploring MP0533 in combination with other AML therapies, and several consortia have approached the Company with interest in conducting such studies.

MP0632 is a logic-gated T cell engager designed for conditional, tumor-localized immune activation in the presence of mesothelin (MSLN) and EpCAM, two tumor-associated antigens highly co-expressed in ovarian, endometrial, pancreatic and other solid tumors. The Company will present additional pre-clinical data on MP0632 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) in November 2026.

Corporate Governance Highlights

Clare Fisher, SVP for Global Business Development and M&A at BeOne Medicines, was elected by shareholders to the Molecular Partners Board of Directors at the Annual General Meeting (AGM) in April 2026. Clare brings extensive business and corporate development experience in the pharmaceutical and biotech industries.

All other motions proposed by the Board of Directors at the AGM were also approved by the shareholders of the Company.

H1 2026 Operational and Financial Highlights

Financial position of CHF 67.9 million in cash and cash equivalents as per June 30, 2026
Net cash used in operating activities CHF 25.0 million in H1 2026
Operating loss of CHF 27.0 million and net loss of CHF 26.7 million in H1 2026
Company expected to be funded into late 2027, excluding potential payments from R&D partnerships
The H1 2026 Financial Statements are available on the Company’s website.

Key figures as of June 30, 2026 (unaudited) H1 2026 H1 2025 Change
(CHF million, except per share, FTE data)
Total revenues and other income —
—
—

R&D expenses (19.0)
(22.6)
3.6

SG&A expenses (8.0)
(8.2)
0.2

Restructuring expenses —
(2.7)
2.7

Total operating expenses (incl depr. & amort.) (27.0)
(33.5)
6.5

Net result (26.7)
(37.2)
10.5
Basic net result per share (in CHF) (0.7)
(1.0)
0.3

Net cash from (used in) operating activities (25.0)
(30.2)
5.2

Cash & cash equivalents (incl. short-term time deposits) 67.9
114.5
(46.6)

Total shareholders’ equity 58.5
106.7
(48.1)

Number of total FTE 116.7
153.0
-36.3

Financial and Business Outlook
For the full year 2026, at constant exchange rates, the Company maintains its previously reported forecast with total operating expenses of CHF 45-55 million expected, including approximately CHF 6 million of non-cash effective costs for share-based payments, IFRS pension accounting and depreciation.

The Company’s cash and cash equivalents and short-term time deposits were CHF 67.9 million (USD ~84 million) as of June 30, 2026 and based on current operating assumptions, is expected to be sufficient to fund its operating expenses and capital expenditure requirements into late 2027.

(Press release, Molecular Partners, AUG 25, 2026, View Source [SID1234670300])

On August 25, 2026 Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") reported that the first patient has been dosed in a Phase 3 study evaluating ASP2138 in combination with chemotherapy and pembrolizumab as first-line treatment in adults with locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors are Claudin 18.2 (CLDN18.2)-positive and HER2-negative.1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This milestone marks an important step in Astellas’ commitment to advancing CLDN18.2 science through a portfolio of approved treatments and investigational assets.

Despite recent advances, many people with advanced gastric and GEJ cancers continue to face poor outcomes, with median progression-free survival of 6 to 7 months with non-CLDN18.2 directed current standard of care.2 Recognizing the importance of continued research into new treatments, Astellas is working to deepen understanding of CLDN18.2 and exploring multiple scientific approaches that may help address different patient needs.

ASP2138 is an investigational subcutaneously administered bispecific antibody designed to bind to CLDN18.2, a protein expressed on certain tumor cells, and CD3-positive T cells, a type of white blood cell with the ability to kill cancer cells.1,3 By binding to both targets, ASP2138 is intended to bring these T cells closer to CLDN18.2-expressing tumor cells and activate their anti-tumor response.4

Tadaaki Taniguchi, M.D., Ph.D., Chief Research and Development Officer, Astellas:
"The first patient dosed in this Phase 3 study is an important milestone for ASP2138 and for our broader work in CLDN18.2. By advancing multiple scientific approaches, we are building the evidence needed to better understand how CLDN18.2-targeted innovation may help address patient needs."

As Astellas’ lead program within its Immuno-Oncology Primary Focus, the ASP2138 Phase 3 study supports the Company’s execution of its Corporate Strategic Plan, including its ambition to initiate five or more Phase 3 or pivotal studies by fiscal year 2027. Astellas will share updates as the study progresses, in line with applicable disclosure requirements and company practice.

(Press release, Astellas, AUG 25, 2026, View Source [SID1234670297])

On August 24, 2026 VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA"), an emerging leader in the design and development of next-generation cancer therapeutics, and Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a company redefining the discovery and development of best-in-class oligonucleotide therapeutics, reported initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (AOCs) for the treatment of autoimmune and chronic immune diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In early in vitro studies, an AOC candidate sourced by combining both parties’ technologies and expertise demonstrated greater potency compared to the equivalent unconjugated, naked oligonucleotide, underlining the future therapeutic potential of the approach. Encouraged by these results, both parties are now discussing the next steps in this alliance. AOCs are increasingly seen as a potentially transformative approach in precision medicine, enabling targeted delivery of therapeutic oligonucleotides to disease-specific cells. Recent clinical advancements have demonstrated their potential in treating a broad range of diseases by overcoming traditional challenges like poor bioavailability and off-target effects.

"Achieving this milestone in our collaboration with Secarna in less than a year demonstrates that our conjugation technology powered by our proprietary click chemistry can be applied efficiently within partnerships beyond our company’s primary focus areas in solid tumors," commented Christoph Erkel, Ph.D., Chief Scientific Officer of VERAXA. "We look forward to continuing our collaboration with Secarna, a leading innovator in oligonucleotide-based therapeutics and unlocking the breadth of opportunities in this emerging drug class."

"While our oligonucleotide pipeline advances and other delivery strategies for our oligonucleotide medicines continue to be very relevant, antibody-guided oligonucleotides offer distinct advantages due to the selective targeting mechanism provided by the antibody carrier," said Konstantin Petropoulos, Ph.D., Chief Executive Officer of Secarna Pharmaceuticals.

(Press release, Veraxa Biotech, AUG 24, 2026, View Source [SID1234670310])

On August 24, 2026 TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, reported an update on its activities, including the strategic development options for its lead oncology asset, NOX-A12.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Following comprehensive discussions and due diligence over recent months, TME Pharma has advanced conversations with two potential partners. The company is now approaching the decision-making stage to select the optimal partner and best path forward for the late-stage development and commercialization of NOX-A12.

Strategic Decision Framework & Value Creation
The evaluation of these final strategic options extends beyond transactional valuation and financial terms. TME Pharma is strictly focused on structuring the continuation of the landmark GLORIA trial in a manner that creates the highest long-term value. Key strategic parameters currently under final review include:

Trial Architecture & Regulatory Pathways: Maximization of the likelihood and confidence that the next step of clinical development will be funded and conducted by selecting a committed partner who is aligned with TME Pharma in the goal to perform the upcoming GLORIA study in a way that creates optimal additional value.
Commercial potential: Structuring the research framework to ensure that NOX-A12 reaches its full peak revenue potential within the most favorable timeframe to maximize patent-protected revenues.
Financial conditions: TME Pharma NV and its shareholders need to have a clear picture of a solid short-term future so that there is clarity regarding cash flow. Future potential value must be secured if the drug can be successfully brought to market.

Robust Scientific Validation and Significant Peak Sales Potential for NOX-A12
The strong clinical foundation of NOX-A12 in glioblastoma—an aggressive form of brain cancer with limited treatment options—is supported by compelling data from the GLORIA trial. The efficacy of the NOX-A12 "Triple Therapy" combination (NOX-A12, radiotherapy, and anti-VEGF / bevacizumab) was recently highlighted in a high-impact peer-reviewed publication in Nature Communications, demonstrating significantly improved overall survival (19,9 months against 9,5 months) compared to standard-of-care benchmark cohorts.

Building on these findings, TME Pharma has a randomized, controlled Phase 2 trial protocol ready-to-go in Germany and approved in the US, secured Fast Track Designation from the U.S. FDA and Orphan Drug Designation (granted by both the U.S. FDA and the European Medicines Agency, EMA) for NOX-A12 in glioblastoma. The Total Addressable Market for Glioblastoma is estimated at 2.5 billion. With estimated peak sales potential (upon successful market approval and commercialization) expected of approximately $1 billion, NOX-A12 represents a highly valuable flagship asset capable of transforming care in treatment-resistant solid tumors.

Capitalizing on Favorable Biotech Market Dynamics
TME Pharma has observed a clear improvement in market sentiment, characterized by increased demand from the sector for the acquisition and joint development of promising clinical-stage drugs. In addition, the stock markets are showing a positive trend, with renewed capital inflows into biotech companies.

TME Pharma is well-positioned to capitalize on these favorable market conditions, supported by a strong asset portfolio and positive outlook. Furthermore, as announced on March 9, 2026, the company’s financial flexibility has been extended into the second quarter of 2027, providing the flexibility to find the optimal partner for NOX-A12.

"Our discussions in the last months have yielded concrete strategic interest from two parties. As we enter the final evaluation phase, our priority is to select the partner and structuring strategy that maximizes both the commercial value of NOX-A12 and its clinical benefit for patients. We look forward to updating the market as soon as a decision has been made." Said Diede van den Ouden, CEO of TME Pharma NV

NOX-E36
The study announced in January has now been completed, and its objective to establish and validate a detection method for toxicology studies to support clinical ophthalmology development has been successfully achieved.
In addition, TME Pharma continues to explore partnering opportunities for NOX-E36 and will update the market if and when there is a concrete development to report.

GRDC and alternative activities
On November 5th 2025, TME Pharma announced that it had signed a LOI with a German Resource Development Company (‘GRDC’). TME Pharma has decided not to continue its collaboration with GRDC.

As a publicly traded holding company, TME Pharma also intends to develop alternative business activities in addition to entering into licensing agreements for its lead biotech assets. The objective is to create additional value for shareholders and to generate cash flow from the Company’s own operations.

TME Pharma will therefore continue its search for sound and future-proof companies and activities. It will inform the market when interesting opportunities arise and seek shareholder approval before making a final decision.

Share transaction by the CEO
TME Pharma today announces that it has received notification that Diede van den Ouden, Chief Executive Officer and a Person Discharging Managerial Responsibilities ("PDMR"), has sold 460,050 ordinary shares on Euronext Growth Paris on August 19, 2026 at an average price of EUR 0,1107 per share, pursuant to an irrevocable sell instruction with pre-set price limits and a volume cap, placed with his broker on May 20, 2026 and recorded by the broker’s compliance department. Following this transaction, Mr. Van den Ouden interests remain aligned with those of shareholders. Mr. van den Ouden holds 2,214,950 ordinary shares, approximately 6.8 million warrants (provided as part of two loan agreements by Mr. van den Ouden for a total amount of € 520,956 entered into in May 2025 and and August 2025) and 3.2 million options in the Company. The transaction has been notified to the AFM in accordance with Article 19 of the Market Abuse Regulation, and the overview of the CEO’s transactions in the Documentation section of the Company’s website has been updated accordingly. The orders were solely intended to diversify the risks across the entire portfolio. Currently, the broker still has 3 irrevocable sell instructions from Mr. van den Ouden outstanding: 214,950 ordinary shares with a pre-set minimum price limit of €0.11, and two irrevocable sell instructions of 1.0 million ordinary shares each with pre-set minimum price limits of €0.14 and €0.17, respectively, capped at a maximum of 15% of the daily trading volume, and valid until the end op 2026.

(Press release, TME Pharma, AUG 24, 2026, View Source [SID1234670309])

On August 24, 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, reported that the first patient has been dosed in MODeFIRe-1 (clinicaltrials.gov identifier NCT07745361), a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor (AR) inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with AR mutations. The study follows encouraging clinical data previously shared from the Company’s Phase 1/2 study of MRT-2359 in combination with enzalutamide in heavily pretreated mCRPC patients. MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered and developed by Monte Rosa.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Dosing the first patient in MODeFIRe-1 is an important step in advancing MRT-2359 as a potential therapy for patients with mCRPC with AR mutations, a population with limited therapeutic options," said Filip Janku, M.D., Ph.D., Chief Medical Officer of Monte Rosa Therapeutics. "This study builds on the encouraging results we observed in our Phase 1/2 study of MRT-2359 in combination with enzalutamide. As we disclosed previously, in that study of heavily pretreated, advanced CRPC patients – including those who had progressed on prior second-generation AR inhibitors, chemotherapy, and radioligand therapy – 5 of 5 patients with AR mutations demonstrated a PSA response, with a 100% disease control rate and two RECIST responses. MODeFIRe-1 pairs MRT-2359 with apalutamide using a design intended to efficiently further evaluate and potentially confirm clinical activity in this population. We believe this study can position MRT-2359 for advancement into registrational development if the data continue to support our earlier results, with the potential to also extend clinical benefit to additional AR-driven patient populations including patients without prior second-generation AR inhibitors, as well as into combinations with radioligand therapies independent of AR status."

MODeFIRe-1 will evaluate MRT-2359 at a dose of 0.5 mg administered orally on a 21 days on, 7 days off schedule over 28-day cycles, in combination with apalutamide. The study will enroll up to 25 patients with mCRPC with AR mutations, utilizing a Simon’s two-stage design. Eligible patients must have AR mutations, PSA with or without RECIST-measurable disease, and prior treatment with a second-generation AR inhibitor. Study endpoints include PSA response, RECIST response, duration of response, radiographic progression-free survival (rPFS), PSA progression-free survival, and safety.

Enrollment in the initial Phase 1/2 study expansion arm in patients with advanced CRPC has been completed. A total of 6 patients with AR mutations were enrolled and treated with MRT-2359 in combination with enzalutamide. Monte Rosa plans to provide an update on this patient subset by the end of the year. Interim data were presented at the ASCO (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU) in February.

About MRT-2359
MRT-2359 is a potent, highly selective, and orally bioavailable investigational molecular glue degrader (MGD) of GSPT1. MYC-driven cancers, including prostate cancer, depend on enhanced translation of oncoproteins to support rapid growth. MRT-2359 exploits this therapeutic vulnerability by disrupting translation through selective degradation of the translation termination factor GSPT1. MRT-2359 treatment reduced cellular abundance of many prostate cancer-relevant oncoproteins, including AR, MYC, and Cyclin D1-E2F, and demonstrated robust anti-tumor activity across multiple preclinical models of metastatic castration-resistant prostate cancer (mCRPC). MRT-2359 is being evaluated in combination with apalutamide in MODeFIRe-1, a Phase 2 study in mCRPC patients with AR mutations. In a Phase 1/2 study, the combination of MRT-2359 with the AR inhibitor enzalutamide demonstrated encouraging early signals of clinical response in mCRPC patients with AR mutations.

(Press release, Monte Rosa Therapeutics, AUG 24, 2026, View Source [SID1234670308])